Sandoz, a division of Novartis, is a global leader in the pharmaceutical industry, headquartered in Switzerland (CH). Founded in 1886, Sandoz has established itself as a pioneer in generic and biosimilar medicines, focusing on high-quality, affordable healthcare solutions. With a strong presence in Europe, North America, and emerging markets, the company is dedicated to improving patient access to essential medications. Sandoz's core offerings include a diverse range of generic pharmaceuticals, biosimilars, and over-the-counter products, distinguished by their rigorous quality standards and innovative approaches. The company has achieved significant milestones, including the launch of several groundbreaking biosimilars, solidifying its position as a trusted partner in the healthcare sector. With a commitment to sustainability and patient-centric solutions, Sandoz continues to shape the future of medicine.
How does Sandoz's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Sandoz's score of 71 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Sandoz reported total carbon emissions of approximately 1,988,500,000 kg CO2e. This includes Scope 1 emissions of about 82,100,000 kg CO2e, Scope 2 emissions of approximately 157,600,000 kg CO2e, and significant Scope 3 emissions totalling around 1,748,800,000 kg CO2e. The company has set ambitious targets to reduce its emissions, aiming for a 30% reduction in Scope 1 and Scope 2 emissions from a 2020 baseline by 2030. Additionally, Sandoz is committed to reducing its Scope 1 and Scope 2 emissions to near zero by 2025. In 2023, Sandoz's total emissions were about 2,260,100,000 kg CO2e, with Scope 1 emissions at approximately 86,200,000 kg CO2e and Scope 2 emissions around 122,300,000 kg CO2e. The company has disclosed its emissions across all relevant scopes, demonstrating transparency in its climate impact. Sandoz is also committed to achieving net zero emissions by 2050, reflecting its long-term dedication to sustainability within the pharmaceuticals sector. The emissions data and reduction targets are sourced from Sandoz Group AG, ensuring that the information is accurate and relevant to their corporate climate strategy.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 75,620,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 158,430,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 |
Sandoz's Scope 3 emissions, which decreased by 15% last year and decreased by approximately 15% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sandoz has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Sandoz's sustainability data and climate commitments